Your browser doesn't support javascript.
loading
Complete response to tislelizumab in a metastatic urothelial carcinoma after surgery associated with high tumor mutational burden: a case report.
Jin, Jing; Yang, Qidong; Yu, Yangyang; Chen, Lin; Pan, Shouhua.
Affiliation
  • Jin J; Department of Urology, Shaoxing People's Hospital (Shaoxing Hospital, Zhejiang University School of Medicine), Zhejiang, China.
  • Yang Q; The State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., LtdThe Medical Department, Jiangsu Simcere Diagnostics Co., LtdNanjing Simcere Medical Laboratory Science Co., Ltd, Nanjing, China.
  • Yu Y; The State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., LtdThe Medical Department, Jiangsu Simcere Diagnostics Co., LtdNanjing Simcere Medical Laboratory Science Co., Ltd, Nanjing, China.
  • Chen L; The State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., LtdThe Medical Department, Jiangsu Simcere Diagnostics Co., LtdNanjing Simcere Medical Laboratory Science Co., Ltd, Nanjing, China.
  • Pan S; Department of Urology, Shaoxing People's Hospital (Shaoxing Hospital, Zhejiang University School of Medicine), Zhejiang, China.
Anticancer Drugs ; 34(4): 595-598, 2023 04 01.
Article in En | MEDLINE | ID: mdl-36730313
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urinary Bladder Neoplasms / Carcinoma, Transitional Cell / Urologic Neoplasms Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Anticancer Drugs Journal subject: ANTINEOPLASICOS Year: 2023 Document type: Article Affiliation country: China
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urinary Bladder Neoplasms / Carcinoma, Transitional Cell / Urologic Neoplasms Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Anticancer Drugs Journal subject: ANTINEOPLASICOS Year: 2023 Document type: Article Affiliation country: China